Protalix BioTherapeutics Unveils Promising Phase 2 Study Results for PRX-115 in Gout Management

Protalix BioTherapeutics, a leading biopharmaceutical firm, has revealed noteworthy findings concerning its investigational drug PRX-115 aimed at treating uncontrolled gout. This information was presented during the American College of Rheumatology's Convergence 2026, held in Orlando, Florida.

Gout is a prevalent metabolic disorder characterized by elevated levels of uric acid in the blood, which leads to severe joint pain and inflammation. Approximately 11.3 million people in the U.S. suffer from gout, with many failing to meet the desired uric acid levels despite existing treatments. The company aims to address this gap with PRX-115, which leverages a unique plant-based protein expression system for the development of therapeutic agents.

Highlights from the Phase 1 Study

In earlier Phase 1 trials, PRX-115 demonstrated a solid lowering effect on plasma uric acid levels, keeping them under the target of 6.0 mg/dL for as long as 12 weeks after a single infusion of 36 mg. This impressive performance indicates the potential for a more infrequent dosing regimen as compared to current treatments, which often require more frequent administration.

During the Phase 2 RELEASE study, which focuses on the potential of PRX-115 for uncontrolled gout patients, the drug was observed to significantly reduce uric acid levels for extended periods. Data collected suggests that after a single higher dose, PRX-115 maintained measurable plasma levels for 85 days, reinforcing its therapeutic benefits.

Increased Dosing Intervals Tested

The Phase 2 study will assess two different administering schedules: one dosing every four weeks without methotrexate, and another every eight weeks alongside methotrexate. The primary objective of this clinical investigation is to demonstrate a reduction in the serum uric acid levels of below 6.0 mg/dL for at least 80% of the time throughout the six-month period.

Protalix believes that this study may pave the way for a revolutionary treatment option for those struggling with uncontrolled gout, allowing for a less burdensome treatment routine. Dror Bashan, President and CEO, elaborated on PRX-115's potential to address significant unmet medical needs and how the Phase 1 data supports the idea of less frequent dosing leading to better adherence from patients.

Safety and Tolerability

Safety data from the initial studies suggest that PRX-115 is generally well tolerated by participants, with mostly mild to moderate related adverse effects. There was one occurrence of anaphylaxis which was resolved and did not hinder the patient's participation. Notably, there were no other serious adverse events reported beyond this isolated incident.

Conclusion and Future Prospects

As Protalix BioTherapeutics moves forward with its research and anticipates the primary results of the Phase 2 RELEASE study in the latter half of 2027, the emerging potential for PRX-115 points toward a promising future in the treatment realm for uncontrolled gout. With an estimated 180,000 patients in the U.S. affected, the demand for effective therapies remains high, making the advancements in PRX-115 critical for both the company and patients alike.

Protalix continues to focus not only on refining this promising treatment but also on ensuring that the production and administration of PRX-115 remain safe and effective for those who need it most. Moving ahead, the company is positioned to significantly impact the field of gout management and beyond, with an innovative approach in drug development and a commitment to addressing challenging disease states.